Aerovate Therapeutics has announced that former Proteon Therapeutics President and CEO Timothy Noyes has been named CEO and elected to the company’s board of directors. Noyes was most recently CEO of Arcuate Therapeutics, and he previously served in executive roles at Genzyme and GelTex Pharmaceuticals after beginning his career at Merck. Aerovate’s lead candidate is AV-101 dry powder imatinib for the treatment of pulmonary arterial hypertension.
Aerovate Founder and President Benjamin Dake said, “Tim is an incredible leader with deep experience in drug development, commercialization and company building. We are excited to welcome him to Aerovate as we look to advance our novel inhaled aerosol drug candidate into efficacy trials for the treatment of pulmonary arterial hypertension, also known as PAH.”
Noyes commented, “I am excited to join the team as we work to advance a potentially meaningful therapy for people living with PAH. PAH can negatively impact nearly every aspect of a person’s life, and we are committed to developing our lead drug candidate, AV-101, to determine whether it is safe and effective and could potentially provide patients with a new treatment alternative.”
Read the Aerovate Therapeutics press release.
